Merck & Co., Inc: Glioblastoma trials
The registry lists 13 Glioblastoma studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 4Phase 2 4Phase 3 1Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
- A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)TerminatedNCT02296476Phase 2Results posted
- Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)CompletedNCT00725010Results posted
- Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)CompletedNCT00723827Results posted
- Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)CompletedNCT00704808Results posted
- Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)CompletedNCT00686725Phase 4Results posted
- Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)CompletedNCT00684567Phase 2Results posted
- The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)CompletedNCT00392171Phase 2Results posted
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
- Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)CompletedNCT01295632Phase 1
- Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
- Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)CompletedNCT00335075Phase 3
- Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)CompletedNCT00087451Phase 1